We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 2,591

Boston Scientific files second IPR petition against UAB Patent

  • Knobbe Martens Olson & Bear LLP
  • -
  • USA
  • -
  • April 16 2015

Boston Scientific Corporation ("Boston Scientific") filed a petition with the Patent Trial and Appeal Board on April 10, 2015 requesting inter partes

Section 337’s potential for defending biologics market share against biosimilars

  • Sterne Kessler Goldstein & Fox
  • -
  • USA
  • -
  • April 16 2015

Enforcement of biologic patents at the United States International Trade Commission under Section 337 provides certainty and tactical advantages to

Intellectual Property Laws Amendment Act 2015 update on recent changes to Australia’s intellectual property legislation

  • Davies Collison Cave
  • -
  • Australia, New Zealand
  • -
  • April 15 2015

The Intellectual Property Laws Amendment Act 2015 (Cth) received Royal Assent on 25 February 2015. Although some changes under the Act came into

Patent controller revokes Boehringer’s patent based on Cipla’s post-grant opposition

  • Lakshmikumaran & Sridharan
  • -
  • India
  • -
  • April 15 2015

In its latest rejection of a pharmaceutical patent the Patent Office rejected Patent 254813, granted to Boehringer Ingelheim Pharma Gmbh, in a

Federal Circuit addresses damages in the Hatch-Waxman context

  • Morrison & Foerster LLP
  • -
  • USA
  • -
  • April 14 2015

On April 7, 2015, the United States Court of Appeals for the Federal Circuit issued its decision in Astrazeneca AB v. Apotex Corp., No. 2014-1221

FDA opens door to the US biosimilars market

  • Fitzpatrick, Cella, Harper & Scinto
  • -
  • USA
  • -
  • April 13 2015

March 6 2015 marked a turning point for the emerging US biosimilars market. The Food and Drug Administration (FDA) approved Sandoz's application to

Statements in a generic’s Product Monograph were not found to amount to an inducement to infringe

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

The Court has allowed a motion to strike portions of an application pursuant to Paragraph 6(5)(b) of the PM(NOC) Regulations. The generic respondent

Patent found valid and infringed even if the method of infringement was not in the minds of the inventors

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

AstraZeneca sued Apotex for infringement of its patent relating to the formulation of the drug omeprazole. Apotex argued invalidity and

Application for an order of prohibition is dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

The Court found that Teva’s allegation of obviousness was justified. As a result, the application was dismissed

Although moot, Minister of Health is found to be wrong to issue NOCs to generic companies without first requiring them to serve a notice of allegation

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

Actelion has persuaded the Court to quash the NOCs provided to two generic companies after they were awarded by the Minster of Health. However, the